Abeona Therapeutics (NASDAQ:ABEO) has been assigned a $36.00 price target by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 128.57% from the stock’s previous close.

Several other equities analysts have also weighed in on the company. Royal Bank of Canada reissued a “buy” rating and set a $26.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, January 24th. Maxim Group reissued a “buy” rating and set a $35.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, February 7th. HC Wainwright set a $30.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a report on Thursday, January 4th. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. Finally, BidaskClub downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $27.33.

How to Become a New Pot Stock Millionaire

Abeona Therapeutics (NASDAQ:ABEO) opened at $15.75 on Tuesday. Abeona Therapeutics has a twelve month low of $4.55 and a twelve month high of $22.75. The firm has a market capitalization of $660.00, a price-to-earnings ratio of -23.86 and a beta of 1.30.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Abeona Therapeutics had a negative net margin of 3,263.92% and a negative return on equity of 24.57%. The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.24 million. Abeona Therapeutics’s revenue for the quarter was down 16.0% compared to the same quarter last year. equities analysts anticipate that Abeona Therapeutics will post -0.68 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Teacher Retirement System of Texas purchased a new stake in shares of Abeona Therapeutics during the fourth quarter worth $163,000. MetLife Investment Advisors LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth $194,000. SG Americas Securities LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth $218,000. Virtu Financial LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth $246,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Abeona Therapeutics in the second quarter worth $275,000. Hedge funds and other institutional investors own 62.64% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics (ABEO) PT Set at $36.00 by Cantor Fitzgerald” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/abeona-therapeutics-abeo-pt-set-at-36-00-by-cantor-fitzgerald/1954774.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.